These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 25830296)

  • 41. Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study.
    Lin JH; Chen WC
    Kaohsiung J Med Sci; 2002 Aug; 18(8):379-85. PubMed ID: 12476680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature.
    Suchonwanit P; Iamsumang W; Leerunyakul K
    J Dermatolog Treat; 2022 Mar; 33(2):643-648. PubMed ID: 32538225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
    Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
    Arias-Santiago S; Camacho-Martínez FM
    Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
    [No Abstract]   [Full Text] [Related]  

  • 45. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
    Price VH; Menefee E; Sanchez M; Ruane P; Kaufman KD
    J Am Acad Dermatol; 2002 Apr; 46(4):517-23. PubMed ID: 11907500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil
    Gentile P; Garcovich S
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
    Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.
    Rossi A; Mari E; Scarno M; Garelli V; Maxia C; Scali E; Iorio A; Carlesimo M
    Int J Immunopathol Pharmacol; 2012; 25(4):1167-73. PubMed ID: 23298508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature.
    Boychenko O; Bernstein RM; Schweiger ES
    Cutis; 2012 Aug; 90(2):73-6. PubMed ID: 22988650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia.
    Ryu HJ; Kwon DY
    Dermatol Surg; 2014 May; 40(5):595-7. PubMed ID: 24533595
    [No Abstract]   [Full Text] [Related]  

  • 51. Finasteride-associated male infertility.
    Chiba K; Yamaguchi K; Li F; Ando M; Fujisawa M
    Fertil Steril; 2011 Apr; 95(5):1786.e9-11. PubMed ID: 21193189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Caspase-1 level is higher in the scalp in androgenetic alopecia.
    de Rivero Vaccari JP; Sawaya ME; Brand F; Nusbaum BP; Bauman AJ; Bramlett HM; Dietrich WD; Keane RW
    Dermatol Surg; 2012 Jul; 38(7 Pt 1):1033-9. PubMed ID: 22404322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of Postoperative Finasteride Therapy on Recurrence of Gynecomastia After Mastectomy in Men Taking Finasteride for Alopecia.
    Lee SG; Park PJ; Lee SR; Koo BH; Byun GY; Kim MJ; Kang HJ; Kim S; Oh BS; Lee YH
    Am J Mens Health; 2019; 13(5):1557988319871423. PubMed ID: 31552775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia.
    Kim H; Ryu C; Lee M; Lee KR; Kim J
    Adv Ther; 2024 Jul; 41(7):2936-2952. PubMed ID: 38833144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss).
    Kaufman KD; Rotonda J; Shah AK; Meehan AG
    Eur J Dermatol; 2008; 18(4):400-6. PubMed ID: 18573712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia.
    Irwig MS
    Curr Opin Endocrinol Diabetes Obes; 2015 Jun; 22(3):248-53. PubMed ID: 25871957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain.
    Motofei IG; Rowland DL; Manea M; Georgescu SR; Păunică I; Sinescu I
    Clin Drug Investig; 2017 Jun; 37(6):511-517. PubMed ID: 28161756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 60. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results.
    Price VH; Menefee E; Sanchez M; Kaufman KD
    J Am Acad Dermatol; 2006 Jul; 55(1):71-4. PubMed ID: 16781295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.